Table 4.
CVD Preventive Recommendations by Practice Type According to Risk Level of Experimental Case
| Calculated Risk Level of Case | ||||||
|---|---|---|---|---|---|---|
| High | Intermediate | Low | ||||
| Practice Type | ||||||
| Solo (N=139) | Nonsolo (N=361) | Solo (N=139) | Nonsolo (N=361) | Solo (N=139) | Nonsolo (N=361) | |
| Physical activity | 91 | 91 | 93 | 93 | 90 | 86 |
| Cardiac rehabilitation | 13 | 10 | 5 | 2 | 3 | 2 |
| Dietary counseling | 80 | 81 | 79 | 77 | 74 | 76 |
| Weight management | 73 | 75 | 71 | 73 | 25 | 23 |
| Dietary supplementation | 17 | 14* | 16 | 12 | 15 | 13 |
| Pharma BP control | 87 | 87 | 49 | 49 | 4 | 1 |
| Pharma Lipid control | 49 | 48 | 50 | 43 | 81 | 74 |
| Aspirin therapy | 85 | 79 | 73 | 64 | 49 | 36* |
| Hormone therapy | 0 | 0 | 0 | 0 | 1 | 1 |
Values are percentages.
*
Significant difference between solo and nonsolo practitioners at P<.05, using a multivariable logistic regression model controlling for physician specialty, gender, and age.
CVD, cardiovascular disease; Pharma, pharmacological; BP, blood pressure.